1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow AVE1625: new trials by email Literature Review of AVE1625 trials Research Report on AVE1625
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia AVE1625, placebo - Schizophrenia | Phase 2 | Terminated | Sanofi | 873 | 2007-02-01 | 2016-05-18 |
| Activity of AVE1625 in Mild to Moderate Alzheimer's Patients. AVE1625 - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Sanofi | 162 | 2006-09-01 | 2008-12-19 |
Alzheimer Disease (1) · Schizophrenia (1)
Sanofi (2)
United States (2) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Sweden (1)